Mode Selection Trial in Sinus Node Dysfunction (MOST)
Launched by MT. SINAI MEDICAL CENTER, MIAMI · Oct 27, 1999
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Permanent pacing is estimated to cost one billion dollars annually in health care costs in the United States. Initially, pacing was primarily confined to ventricular pacing with limited sensing, programming and pacing capacity. Tremendous growth has occurred in pacing technology, making available dual chamber pacing with sophisticated sensing, pacing, and rate control. These more advanced pacemakers are more costly and complicated to place surgically.
One of the most common indications for pacing is sick sinus syndrome. Initial therapy is usually medical to inhibit the tachyar...
Gender
ALL
Eligibility criteria
- • Men and women with sick sinus syndrome.
About Mt. Sinai Medical Center, Miami
Mount Sinai Medical Center in Miami is a leading healthcare institution renowned for its commitment to advanced medical research and clinical excellence. As a prominent sponsor of clinical trials, the center focuses on innovative therapies and cutting-edge treatments across various medical disciplines. With a team of experienced researchers and healthcare professionals, Mount Sinai aims to enhance patient care through rigorous scientific inquiry and collaboration, ultimately contributing to the advancement of medical knowledge and the improvement of health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Gervasio Lamas
Icahn School of Medicine at Mount Sinai
Kerry Lee
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials